WELLESLEY HILLS, Massachusetts, April 19, 2010 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. (Finn), Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. (Epix), announced today that the MRI imaging intellectual properties will be auctioned on May 28, 2010. The assets of Epix were transferred to him on July 20, 2009 and he is liquidating them for the benefit of Epix creditors. He recently reached an agreement with Bayer Schering Pharma that permits the sale of the MRI imaging programs.
EP-2104R is a gadolinium-based MRI thrombus imaging agent with a potential indication for stroke workup. It is a first-in-class fibrin binding agent that has completed a Phase 2 proof-of-concept study.
Persons interested in bidding must sign a Confidentiality Disclosure Agreement (CDA) obtained from Finn's Office - IPSALESERVICES@FINNWARNKEGAYTON.COM or +1-781-237-8840. They will then receive a bid package and access to an electronic data room.
About Joseph F. Finn, Jr., C.P.A.
Joseph F. Finn, Jr., C.P.A. is the owner of the firm Finn, Warnke Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-five (35) years. His most recent Assignments for the Benefit of Creditors in the biotech field include Spherics, Inc., ActivBiotics, Inc. and Prospect Therapeutics, Inc.
For further information, please contact Joseph F. Finn, Jr., C.P.A. at +1-781-237-8840 or IPSALESERVICES@FINNWARNKEGAYTON.COM
SOURCE: Joseph F. Finn, Jr., C.P.A.
CONTACT: Joseph F. Finn, Jr., C.P.A., +1-781-237-8840,email@example.com